MUNSON MEDICAL CENTER
- Type
- Teaching hospital
- Where
- Traverse City, MI
- Medicare CCN
- 230097
- Received
- $307,106 in 149 records, 2019 ($29,099 general, $278,006 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: MUNSON MEDICAL CENTER,CORPORATION Fuzzy (name and state)
- Nonprofit contractor: MUNSON MEDICAL CENTER Fuzzy (name and state)
- Plan sponsor: MUNSON MEDICAL CENTER Fuzzy (name and state)
- Federal award recipient: MUNSON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: MUNSON MEDICAL CENTER Fuzzy (name and state)
- Nonprofit: MUNSON MEDICAL CENTER Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2019 | General payment | 32 | $29,099 |
| 2019 | Research payment | 117 | $278,006 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Merck Sharp & Dohme LLC | 15 | $107,568 | 2019 |
| Abbott Laboratories | 37 | $100,610 | 2019 |
| PFIZER INC. | 1 | $30,055 | 2019 |
| Boston Scientific Corporation | 17 | $21,855 | 2019 |
| BIOVERATIV THERAPEUTICS INC. | 43 | $15,041 | 2019 |
| Medtronic MiniMed, Inc. | 3 | $11,575 | 2019 |
| Medtronic USA, Inc. | 1 | $6,962 | 2019 |
| Tandem Diabetes Care, Inc. | 22 | $6,150 | 2019 |
| BioFire Diagnostics, LLC | 1 | $2,742 | 2019 |
| Bard Peripheral Vascular, Inc. | 1 | $1,276 | 2019 |
| ABIOMED | 1 | $750 | 2019 |
| GE HEALTHCARE | 1 | $710 | 2019 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $677 | 2019 |
| W. L. Gore & Associates, Inc. | 1 | $540 | 2019 |
| Arrow International, Inc. | 1 | $400 | 2019 |
| Siemens Medical Solutions USA, Inc. | 1 | $177 | 2019 |
| Saol Therapeutics Inc. | 1 | $15 | 2019 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 117 | $278,006 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 28 | $25,454 |
| Gift | 2 | $2,757 |
| Charitable Contribution | 2 | $888 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2019-12-31 | Siemens Medical Solutions USA, Inc. | $177 | Charitable Contribution | In-kind items and services | 2019 | ||
| 2019-12-30 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-12-20 | Medtronic MiniMed, Inc. | $3,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Minimed 670G System Device, Durable Pump | 2019 | |
| 2019-12-11 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-12-03 | Abbott Laboratories | $150 | Research payment | Cash or cash equivalent | Xience V coronary stent system Device, Vascular | DAPT study | 2019 |
| 2019-12-02 | Boston Scientific Corporation | $1,350 | Research payment | Cash or cash equivalent | GENERAL TACHY Device, TACHY | LSS OF 4 SITE | 2019 |
| 2019-12-02 | Boston Scientific Corporation | $1,198 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | APPRAISE ATP | 2019 |
| 2019-11-23 | Merck Sharp & Dohme LLC | $118 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treat | 2019 |
| 2019-11-20 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-11-08 | BioFire Diagnostics, LLC | $2,742 | Gift | In-kind items and services | Universal Power Supply for the Torch (58999-60R) Device, Clinical Diagnostics | 2019 | |
| 2019-11-08 | W. L. Gore & Associates, Inc. | $540 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | Post-Market Evaluation of the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface for Treatment of In-Stent Rest | 2019 |
| 2019-10-30 | Abbott Laboratories | $5,717 | Research payment | Cash or cash equivalent | Nanostim Leadless Pacemaker Device, Cardiac Arrhythmias and Heart Failure | A safety and effectiveness trial for a leadless pacemaker system | 2019 |
| 2019-10-30 | Abbott Laboratories | $1,010 | Research payment | Cash or cash equivalent | SJM Tendril MRI Lead Device, Cardiac Arrhythmias and Heart Failure | SJM Brady MRI Post Approval Study | 2019 |
| 2019-10-22 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-10-21 | Abbott Laboratories | $5,750 | Research payment | Cash or cash equivalent | Xience V coronary stent system Device, Vascular | DAPT study | 2019 |
| 2019-10-16 | Abbott Laboratories | $5,325 | Research payment | Cash or cash equivalent | Xience Device, Cardiac Arrhythmias and Heart Failure | XIENCE SHORT DAPT 28 US | 2019 |
| 2019-10-16 | Merck Sharp & Dohme LLC | $721 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in | 2019 |
| 2019-10-16 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-10-16 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-10-16 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-10-07 | Boston Scientific Corporation | $450 | Research payment | Cash or cash equivalent | GENERAL TACHY Device, TACHY | LSS OF 4 SITE | 2019 |
| 2019-10-03 | Abbott Laboratories | $400 | Research payment | Cash or cash equivalent | Xience Device, Cardiac Arrhythmias and Heart Failure | XIENCE SHORT DAPT 28 US | 2019 |
| 2019-09-25 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-09-19 | Medtronic MiniMed, Inc. | $2,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Minimed 670G System Device, Durable Pump | 2019 | |
| 2019-09-16 | Boston Scientific Corporation | $1,332 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | APPRAISE ATP | 2019 |
| 2019-09-16 | Boston Scientific Corporation | $564 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | APPRAISE ATP | 2019 |
| 2019-09-09 | Merck Sharp & Dohme LLC | $717 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treat | 2019 |
| 2019-09-05 | Abbott Laboratories | $350 | Research payment | Cash or cash equivalent | Xience V coronary stent system Device, Vascular | DAPT study | 2019 |
| 2019-09-05 | Abbott Laboratories | $350 | Research payment | Cash or cash equivalent | Xience V coronary stent system Device, Vascular | DAPT study | 2019 |
| 2019-09-05 | Saol Therapeutics Inc. | $15 | Gift | In-kind items and services | Lioresal (baclofen) Drug, Severe Spasticity | 2019 | |
| 2019-09-03 | Boston Scientific Corporation | $450 | Research payment | Cash or cash equivalent | GENERAL TACHY Device, TACHY | LSS OF 4 SITE | 2019 |
| 2019-08-26 | BIOVERATIV THERAPEUTICS INC. | $1,250 | Research payment | Cash or cash equivalent | ALPROLIX Drug, HEMATOLOGY | An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein | 2019 |
| 2019-08-26 | BIOVERATIV THERAPEUTICS INC. | $874 | Research payment | Cash or cash equivalent | ALPROLIX Drug, HEMATOLOGY | An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein | 2019 |
| 2019-08-26 | BIOVERATIV THERAPEUTICS INC. | $874 | Research payment | Cash or cash equivalent | ALPROLIX Drug, HEMATOLOGY | An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein | 2019 |
| 2019-08-26 | BIOVERATIV THERAPEUTICS INC. | $874 | Research payment | Cash or cash equivalent | ALPROLIX Drug, HEMATOLOGY | An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein | 2019 |
| 2019-08-26 | BIOVERATIV THERAPEUTICS INC. | $874 | Research payment | Cash or cash equivalent | ALPROLIX Drug, HEMATOLOGY | An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein | 2019 |
| 2019-08-26 | BIOVERATIV THERAPEUTICS INC. | $874 | Research payment | Cash or cash equivalent | ALPROLIX Drug, HEMATOLOGY | An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein | 2019 |
| 2019-08-26 | BIOVERATIV THERAPEUTICS INC. | $874 | Research payment | Cash or cash equivalent | ALPROLIX Drug, HEMATOLOGY | An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein | 2019 |
| 2019-08-26 | BIOVERATIV THERAPEUTICS INC. | $874 | Research payment | Cash or cash equivalent | ALPROLIX Drug, HEMATOLOGY | An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein | 2019 |
| 2019-08-26 | BIOVERATIV THERAPEUTICS INC. | $123 | Research payment | Cash or cash equivalent | ALPROLIX Drug, HEMATOLOGY | An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein | 2019 |
| 2019-08-23 | Merck Sharp & Dohme LLC | $46,246 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in | 2019 |
| 2019-08-23 | Merck Sharp & Dohme LLC | $21,652 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in | 2019 |
| 2019-08-21 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-08-21 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-08-15 | Abbott Laboratories | $1,750 | Research payment | Cash or cash equivalent | Nanostim Leadless Pacemaker Device, Cardiac Arrhythmias and Heart Failure | A safety and effectiveness trial for a leadless pacemaker system | 2019 |
| 2019-08-15 | Abbott Laboratories | $1,750 | Research payment | Cash or cash equivalent | Nanostim Leadless Pacemaker Device, Cardiac Arrhythmias and Heart Failure | A safety and effectiveness trial for a leadless pacemaker system | 2019 |
| 2019-08-14 | Abbott Laboratories | $650 | Research payment | Cash or cash equivalent | Xience V coronary stent system Device, Vascular | DAPT study | 2019 |
| 2019-08-14 | Abbott Laboratories | $150 | Research payment | Cash or cash equivalent | Xience V coronary stent system Device, Vascular | DAPT study | 2019 |
| 2019-08-13 | Abbott Laboratories | $750 | Research payment | Cash or cash equivalent | Xience V coronary stent system Device, Vascular | DAPT study | 2019 |
| 2019-08-01 | Bayer Healthcare Pharmaceuticals Inc. | $350 | Research payment | Cash or cash equivalent | Xofigo Drug, Oncology | Bay88-8223 Alpharadin Combo with abiraterone in CRPC | 2019 |
| 2019-07-31 | Abbott Laboratories | $4,299 | Research payment | Cash or cash equivalent | Nanostim Leadless Pacemaker Device, Cardiac Arrhythmias and Heart Failure | A safety and effectiveness trial for a leadless pacemaker system | 2019 |
| 2019-07-31 | Abbott Laboratories | $2,700 | Research payment | Cash or cash equivalent | Xience Device, Cardiac Arrhythmias and Heart Failure | XIENCE SHORT DAPT 28 US | 2019 |
| 2019-07-31 | Abbott Laboratories | $1,550 | Research payment | Cash or cash equivalent | SJM Tendril MRI Lead Device, Cardiac Arrhythmias and Heart Failure | SJM Brady MRI Post Approval Study | 2019 |
| 2019-07-25 | Abbott Laboratories | $1,000 | Research payment | Cash or cash equivalent | AMPLATZER Muscular VSD (MuVSD) Occluder Device, Cardiac Arrhythmias and Heart Failure | Closure of Muscular Ventricular Septal Defects with the AMPLATZER Muscular VSD Occluder Post Approval Study | 2019 |
| 2019-07-18 | Abbott Laboratories | $5,500 | Research payment | Cash or cash equivalent | Xience Device, Cardiac Arrhythmias and Heart Failure | XIENCE SHORT DAPT 28 US | 2019 |
| 2019-07-18 | Abbott Laboratories | $2,500 | Research payment | Cash or cash equivalent | Xience Device, Cardiac Arrhythmias and Heart Failure | XIENCE SHORT DAPT 28 US | 2019 |
| 2019-07-11 | Abbott Laboratories | $1,000 | Research payment | Cash or cash equivalent | AMPLATZER Muscular VSD (MuVSD) Occluder Device, Cardiac Arrhythmias and Heart Failure | Closure of Muscular Ventricular Septal Defects with the AMPLATZER Muscular VSD Occluder Post Approval Study | 2019 |
| 2019-07-10 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-07-08 | Abbott Laboratories | $366 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-07-02 | Abbott Laboratories | $9,625 | Research payment | Cash or cash equivalent | Xience V coronary stent system Device, Vascular | DAPT study | 2019 |
| 2019-07-02 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-06-25 | Medtronic MiniMed, Inc. | $5,975 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Minimed 670G System Device, Durable Pump | 2019 | |
| 2019-06-17 | PFIZER INC. | $30,055 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | POLARIS PALBOCICLIB IN HORMONE RECEPTOR POSITIVE ADVANCED BREAST CANCER A PROSPECTIVE MULTICENTER NONINTERVENTIONAL STUD | 2019 |
| 2019-06-17 | Merck Sharp & Dohme LLC | $213 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in | 2019 |
| 2019-06-14 | Boston Scientific Corporation | $855 | Research payment | Cash or cash equivalent | GENERAL TACHY Device, TACHY | LSS OF 4 SITE | 2019 |
| 2019-06-14 | Boston Scientific Corporation | $436 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | APPRAISE ATP | 2019 |
| 2019-06-12 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-06-12 | Merck Sharp & Dohme LLC | $200 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo controlled Study to Evaluate the Safety and Efficacy of Pemetrexed Platinum Chemotherapy | 2019 |
| 2019-06-07 | Abbott Laboratories | $1,290 | Research payment | Cash or cash equivalent | ABSORB Device, Vascular | A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects | 2019 |
| 2019-06-06 | Merck Sharp & Dohme LLC | $17 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treat | 2019 |
| 2019-05-30 | Merck Sharp & Dohme LLC | $3,337 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in | 2019 |
| 2019-05-30 | GE HEALTHCARE | $710 | Charitable Contribution | Cash or cash equivalent | 2019 | ||
| 2019-05-30 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-05-24 | Arrow International, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VPS - ARROW Device, Vascular | 2019 | |
| 2019-05-15 | Abbott Laboratories | $1,755 | Research payment | Cash or cash equivalent | MultiPoint Pacing Device, Cardiac Arrhythmias and Heart Failure | MultiPoint Pacing Post Market Study | 2019 |
| 2019-05-15 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-05-06 | Boston Scientific Corporation | $1,875 | Research payment | Cash or cash equivalent | GENERAL TACHY Device, TACHY | LSS OF 4 SITE | 2019 |
| 2019-05-06 | Boston Scientific Corporation | $1,000 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | APPRAISE ATP | 2019 |
| 2019-05-01 | BIOVERATIV THERAPEUTICS INC. | $1,200 | Research payment | Cash or cash equivalent | ALPROLIX Drug, HEMATOLOGY | An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein | 2019 |
| 2019-05-01 | Abbott Laboratories | $1,011 | Research payment | Cash or cash equivalent | SJM Tendril MRI Lead Device, Cardiac Arrhythmias and Heart Failure | SJM Brady MRI Post Approval Study | 2019 |
| 2019-05-01 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-05-01 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-05-01 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-05-01 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-05-01 | BIOVERATIV THERAPEUTICS INC. | $175 | Research payment | Cash or cash equivalent | ALPROLIX Drug, HEMATOLOGY | An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein | 2019 |
| 2019-05-01 | BIOVERATIV THERAPEUTICS INC. | $175 | Research payment | Cash or cash equivalent | ALPROLIX Drug, HEMATOLOGY | An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein | 2019 |
| 2019-05-01 | BIOVERATIV THERAPEUTICS INC. | $175 | Research payment | Cash or cash equivalent | ALPROLIX Drug, HEMATOLOGY | An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein | 2019 |
| 2019-05-01 | BIOVERATIV THERAPEUTICS INC. | $175 | Research payment | Cash or cash equivalent | ALPROLIX Drug, HEMATOLOGY | An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein | 2019 |
| 2019-05-01 | BIOVERATIV THERAPEUTICS INC. | $175 | Research payment | Cash or cash equivalent | ALPROLIX Drug, HEMATOLOGY | An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein | 2019 |
| 2019-05-01 | BIOVERATIV THERAPEUTICS INC. | $175 | Research payment | Cash or cash equivalent | ALPROLIX Drug, HEMATOLOGY | An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein | 2019 |
| 2019-05-01 | BIOVERATIV THERAPEUTICS INC. | $175 | Research payment | Cash or cash equivalent | ALPROLIX Drug, HEMATOLOGY | An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein | 2019 |
| 2019-05-01 | BIOVERATIV THERAPEUTICS INC. | $175 | Research payment | Cash or cash equivalent | ALPROLIX Drug, HEMATOLOGY | An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein | 2019 |
| 2019-05-01 | BIOVERATIV THERAPEUTICS INC. | $175 | Research payment | Cash or cash equivalent | ALPROLIX Drug, HEMATOLOGY | An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein | 2019 |
| 2019-05-01 | BIOVERATIV THERAPEUTICS INC. | $175 | Research payment | Cash or cash equivalent | ALPROLIX Drug, HEMATOLOGY | An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein | 2019 |
| 2019-05-01 | BIOVERATIV THERAPEUTICS INC. | $175 | Research payment | Cash or cash equivalent | ALPROLIX Drug, HEMATOLOGY | An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein | 2019 |
| 2019-05-01 | BIOVERATIV THERAPEUTICS INC. | $175 | Research payment | Cash or cash equivalent | ALPROLIX Drug, HEMATOLOGY | An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein | 2019 |
| 2019-05-01 | BIOVERATIV THERAPEUTICS INC. | $175 | Research payment | Cash or cash equivalent | ALPROLIX Drug, HEMATOLOGY | An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein | 2019 |
| 2019-05-01 | BIOVERATIV THERAPEUTICS INC. | $175 | Research payment | Cash or cash equivalent | ALPROLIX Drug, HEMATOLOGY | An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein | 2019 |
| 2019-05-01 | BIOVERATIV THERAPEUTICS INC. | $175 | Research payment | Cash or cash equivalent | ALPROLIX Drug, HEMATOLOGY | An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein | 2019 |
| 2019-05-01 | BIOVERATIV THERAPEUTICS INC. | $175 | Research payment | Cash or cash equivalent | ALPROLIX Drug, HEMATOLOGY | An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein | 2019 |
| 2019-05-01 | BIOVERATIV THERAPEUTICS INC. | $175 | Research payment | Cash or cash equivalent | ALPROLIX Drug, HEMATOLOGY | An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein | 2019 |
| 2019-05-01 | BIOVERATIV THERAPEUTICS INC. | $175 | Research payment | Cash or cash equivalent | ALPROLIX Drug, HEMATOLOGY | An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein | 2019 |
| 2019-05-01 | BIOVERATIV THERAPEUTICS INC. | $175 | Research payment | Cash or cash equivalent | ALPROLIX Drug, HEMATOLOGY | An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein | 2019 |
| 2019-05-01 | BIOVERATIV THERAPEUTICS INC. | $175 | Research payment | Cash or cash equivalent | ALPROLIX Drug, HEMATOLOGY | An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein | 2019 |
| 2019-05-01 | BIOVERATIV THERAPEUTICS INC. | $175 | Research payment | Cash or cash equivalent | ALPROLIX Drug, HEMATOLOGY | An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein | 2019 |
| 2019-05-01 | BIOVERATIV THERAPEUTICS INC. | $175 | Research payment | Cash or cash equivalent | ALPROLIX Drug, HEMATOLOGY | An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein | 2019 |
| 2019-05-01 | BIOVERATIV THERAPEUTICS INC. | $175 | Research payment | Cash or cash equivalent | ALPROLIX Drug, HEMATOLOGY | An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein | 2019 |
| 2019-05-01 | BIOVERATIV THERAPEUTICS INC. | $175 | Research payment | Cash or cash equivalent | ALPROLIX Drug, HEMATOLOGY | An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein | 2019 |
| 2019-05-01 | BIOVERATIV THERAPEUTICS INC. | $175 | Research payment | Cash or cash equivalent | ALPROLIX Drug, HEMATOLOGY | An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein | 2019 |
| 2019-05-01 | BIOVERATIV THERAPEUTICS INC. | $175 | Research payment | Cash or cash equivalent | ALPROLIX Drug, HEMATOLOGY | An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein | 2019 |
| 2019-05-01 | BIOVERATIV THERAPEUTICS INC. | $175 | Research payment | Cash or cash equivalent | ALPROLIX Drug, HEMATOLOGY | An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein | 2019 |
| 2019-05-01 | BIOVERATIV THERAPEUTICS INC. | $175 | Research payment | Cash or cash equivalent | ALPROLIX Drug, HEMATOLOGY | An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein | 2019 |
| 2019-05-01 | BIOVERATIV THERAPEUTICS INC. | $175 | Research payment | Cash or cash equivalent | ALPROLIX Drug, HEMATOLOGY | An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein | 2019 |
| 2019-05-01 | BIOVERATIV THERAPEUTICS INC. | $175 | Research payment | Cash or cash equivalent | ALPROLIX Drug, HEMATOLOGY | An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein | 2019 |
| 2019-05-01 | BIOVERATIV THERAPEUTICS INC. | $175 | Research payment | Cash or cash equivalent | ALPROLIX Drug, HEMATOLOGY | An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein | 2019 |
| 2019-05-01 | BIOVERATIV THERAPEUTICS INC. | $175 | Research payment | Cash or cash equivalent | ALPROLIX Drug, HEMATOLOGY | An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein | 2019 |
| 2019-04-24 | Abbott Laboratories | $1,900 | Research payment | Cash or cash equivalent | Nanostim Leadless Pacemaker Device, Cardiac Arrhythmias and Heart Failure | A safety and effectiveness trial for a leadless pacemaker system | 2019 |
| 2019-04-12 | Bard Peripheral Vascular, Inc. | $1,276 | Research payment | Cash or cash equivalent | LUTONIX Device, PERIPHERAL VASCULAR | SAFE-DCB REGISTRY BPV14006 | 2019 |
| 2019-04-01 | Abbott Laboratories | $8,350 | Research payment | Cash or cash equivalent | Xience V coronary stent system Device, Vascular | DAPT study | 2019 |
| 2019-04-01 | Boston Scientific Corporation | $870 | Research payment | Cash or cash equivalent | GENERAL TACHY Device, TACHY | LSS OF 4 SITE | 2019 |
| 2019-03-31 | ABIOMED | $750 | Research payment | Cash or cash equivalent | Impella Device, Cardiology/Vascular Diseases | cVAD Registry | 2019 |
| 2019-03-28 | Medtronic USA, Inc. | $6,962 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Minimed 630G Device, Durable Pump | 2019 | |
| 2019-03-26 | BIOVERATIV THERAPEUTICS INC. | $750 | Research payment | Cash or cash equivalent | ALPROLIX Drug, HEMATOLOGY | Study to Determine the Safety and Efficacy of rFIXFc in Untreated Males With Severe Hemophilia B | 2019 |
| 2019-03-13 | Abbott Laboratories | $1,150 | Research payment | Cash or cash equivalent | Xience V coronary stent system Device, Vascular | Abbott Vascular / XIENCE | 2019 |
| 2019-03-13 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-03-13 | Abbott Laboratories | $50 | Research payment | Cash or cash equivalent | Xience V coronary stent system Device, Vascular | Abbott Vascular / XIENCE | 2019 |
| 2019-03-07 | Merck Sharp & Dohme LLC | $10,000 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treat | 2019 |
| 2019-03-06 | Merck Sharp & Dohme LLC | $21,661 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treat | 2019 |
| 2019-03-06 | Abbott Laboratories | $1,935 | Research payment | Cash or cash equivalent | Absorb Device, Vascular | A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects | 2019 |
| 2019-03-06 | Merck Sharp & Dohme LLC | $818 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treat | 2019 |
| 2019-03-06 | Merck Sharp & Dohme LLC | $545 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treat | 2019 |
| 2019-03-01 | Merck Sharp & Dohme LLC | $1,104 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treat | 2019 |
| 2019-02-19 | Boston Scientific Corporation | $1,020 | Research payment | Cash or cash equivalent | GENERAL TACHY Device, TACHY | LSS OF 4 SITE | 2019 |
| 2019-02-06 | Abbott Laboratories | $2,126 | Research payment | Cash or cash equivalent | MultiPoint Pacing Device, Cardiac Arrhythmias and Heart Failure | MultiPoint Pacing Post Market Study | 2019 |
| 2019-02-04 | Boston Scientific Corporation | $6,000 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | APPRAISE ATP | 2019 |
| 2019-02-04 | Boston Scientific Corporation | $2,500 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | APPRAISE ATP | 2019 |
| 2019-02-04 | Boston Scientific Corporation | $350 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | APPRAISE ATP | 2019 |
| 2019-02-04 | Bayer Healthcare Pharmaceuticals Inc. | $327 | Research payment | Cash or cash equivalent | Xofigo Drug, Oncology | Bay88-8223 Alpharadin Combo with abiraterone in CRPC | 2019 |
| 2019-01-31 | Merck Sharp & Dohme LLC | $213 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treat | 2019 |
| 2019-01-30 | Abbott Laboratories | $5,717 | Research payment | Cash or cash equivalent | Nanostim Leadless Pacemaker Device, Cardiac Arrhythmias and Heart Failure | A safety and effectiveness trial for a leadless pacemaker system | 2019 |
| 2019-01-30 | Abbott Laboratories | $5,144 | Research payment | Cash or cash equivalent | SJM Tendril MRI Lead Device, Cardiac Arrhythmias and Heart Failure | SJM Brady MRI Post Approval Study | 2019 |
| 2019-01-28 | Abbott Laboratories | $14,450 | Research payment | Cash or cash equivalent | Xience V coronary stent system Device, Vascular | Abbott Vascular / XIENCE | 2019 |
| 2019-01-28 | Abbott Laboratories | $50 | Research payment | Cash or cash equivalent | Xience V coronary stent system Device, Vascular | Abbott Vascular / XIENCE | 2019 |
| 2019-01-24 | Abbott Laboratories | $3,000 | Research payment | Cash or cash equivalent | MultiPoint Pacing Device, Cardiac Arrhythmias and Heart Failure | MOre REsponse on Cardiac Resynchronization Therapy (CRT) with MultiPoint Pacing (MPP) | 2019 |
| 2019-01-22 | Boston Scientific Corporation | $855 | Research payment | Cash or cash equivalent | GENERAL TACHY Device, TACHY | LSS OF 4 SITE | 2019 |
| 2019-01-22 | Boston Scientific Corporation | $750 | Research payment | Cash or cash equivalent | GENERAL TACHY Device, TACHY | LSS OF 4 SITE | 2019 |
| 2019-01-16 | Abbott Laboratories | $37 | Research payment | Cash or cash equivalent | CardioMEMS Device, Cardiac Arrhythmias and Heart Failure | CardioMEMS HF System Post Approval Study | 2019 |
| 2019-01-09 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-01-03 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Traverse City, MI, county Grand Traverse County, MI, state Michigan; placed by its city name.
| Measure | Place (city or town) Traverse City, MI | County Grand Traverse County, MI | State Michigan |
|---|---|---|---|
| Population B01003 | 15,593 | 96,166 | 10,077,761 |
| Population, 2020 census P1 | 15,678 | 95,238 | 10,077,331 |
| Median age B01002 | 42.7 | 43.5 | 40.2 |
| Under 18 B01001 | 16.6% | 19.4% | 21.2% |
| 65 and over B01001 | 23.9% | 22.0% | 18.6% |
| Households B11001 | 7,191 | 40,287 | 4,076,369 |
| Foreign born B05002 | 2.5% | 2.0% | 7.2% |
| Median household income B19013 | $74,087 | $81,647 | $72,875 |
| Median family income B19113 | $106,362 | $101,748 | $93,357 |
| Per capita income B19301 | $53,432 | $45,034 | $40,735 |
| Poverty rate B17001 | 12.3% | 9.6% | 13.2% |
| Unemployment rate B23025 | 5.2% | 3.8% | 5.7% |
| Civilian labor force B23025 | 8,267 | 50,787 | 5,018,449 |
| Mean commute (minutes) B08013 | 17.2 | 20.6 | 24.2 |
| Bachelor's degree or higher B15003 | 47.4% | 40.6% | 32.4% |
| Housing units B25001 | 8,479 | 47,003 | 4,622,236 |
| Owner-occupied B25003 | 63.7% | 77.2% | 73.2% |
| Renters B25003 | 36.3% | 22.8% | 26.8% |
| Median home value B25077 | $415,400 | $339,400 | $231,600 |
| Median gross rent B25064 | $995 | $1,288 | $1,129 |
| White, not Hispanic B03002 | 87.7% | 90.5% | 72.4% |
| Black B03002 | 1.3% | 0.8% | 13.1% |
| Hispanic or Latino B03002 | 3.6% | 3.4% | 5.9% |
| Asian B03002 | 1.1% | 0.7% | 3.4% |
| American Indian and Alaska Native B03002 | 0.2% | 0.4% | 0.3% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Traverse City, MI.
Comments